Ignite Creation Date:
2025-12-24 @ 11:53 PM
Ignite Modification Date:
2026-01-02 @ 4:19 PM
Study NCT ID:
NCT00881751
Status:
COMPLETED
Last Update Posted:
2017-09-11
First Post:
2009-04-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Sponsor:
Medical University of South Carolina
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-03
Start Date Type:
None
Primary Completion Date:
2016-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-02
Completion Date Type:
ACTUAL
First Submit Date:
2009-04-14
First Submit QC Date:
None
Study First Post Date:
2009-04-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-06-13
Results First Submit QC Date:
None
Results First Post Date:
2017-09-11
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-08-09
Last Update Post Date:
2017-09-11
Last Update Post Date Type:
ACTUAL